IntroductionHypercalcemia is one of the most frequent electrolyte disorders in patients with malignant diseases [1], presenting in about one quarter of these patients [2]. Hypercalcemia could result from osteolytic lesions or from production of humoral substances like parathyroid hormone-related protein (PTHrP) or uncontrolled synthesis and secretion of 1-25(OH)2D3 by the tumoral cell or macrophages. Within tumor-related etiologies, multiple myeloma, breast, lung, and kidney cancers are the most frequent [3,4]. In these diseases, hypercalcemia has been reported in 30% and 60% of patients with multiple myeloma and T-cell non-Hodgkin lymphoma [1].However, hypercalcemia has only been reported in 7-8% of patients with B-cell non-Hodgkin lymphoma (NHL) and its prevalence and its prognostic value is unclear [2].